Chiome Bioscience (TSE:4583) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4583 Chiome Bioscience Inc TSE:4583
38 GF Score
Price 円69.00
GF Value 円106.02
Valuation Possible Value Trap
! 1 Warning Sign
View Full Analysis

What is Chiome Bioscience FFO per Share?

FFO per Share only applies to REITs.

TSE:4583
38GF Score
Chiome Bioscience Inc TSE:4583
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Chiome Bioscience (TSE:4583) Overvalued in 2026?

Based on GuruFocus' analysis, Chiome Bioscience stock appears to be undervalued. The current stock price of 円69.00 is trading 34.9% below its estimated GF Value™ of 円106.02. GuruFocus considers Chiome Bioscience to be Possible Value Trap.

Key valuation signals for TSE:4583:

  • FFO per Share:
  • GF Value™: 円106.02 vs. price of 円69.00 (34.9% below fair value)
  • GF Score™: 38/100 with 1 warning sign

No single metric tells the full story. See the TSE:4583 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Chiome Bioscience Business Description

Address 3-12-1 Honmachi, No. 6, Sumitomo Fudosan Nishi Shinjuku Building, Shibuya-ku, Tokyo, JPN, 151-0071
Chiome Bioscience Inc is engaged in the discovery and development of antibody drugs, focusing on early-stage research and initial clinical trials. The company operates through two reportable segments: the Drug Discovery segment and the Drug Discovery Support segment. The Drug Discovery segment conducts research on antibody creation for diseases with high unmet medical needs and aims to generate revenue through licensing agreements, upfront payments, milestone payments, and royalties. The Drug Discovery Support segment provides services such as antibody production and related support using proprietary antibody technologies, catering to pharmaceutical and diagnostic companies as well as academic institutions.
38GF Score

Get the complete analysis for TSE:4583

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円69.00
Price
円106.02
GF Value